Pasireotide
- TRADE NAME: Signifor (Novartis)
- INDICATIONS: Cushing's disease
- CLASS: Somatostatin analog
- HALF-LIFE: 12 hours
FDA APPROVAL DATE: 12/14/2012
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Antiarrhythmics, Bromocriptine, Cyclosporine, Drugs prolonging the QT interval
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric